Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_4
2
40%
Ph phase_2
1
20%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

NCT01110707
completed

GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)

NCT01100333
completedphase_4

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

NCT00298025
completedphase_3

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

NCT01185704
terminatedphase_4

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926

Clinical Trials (5)

Showing 5 of 5 trials
NCT01110707Phase 2

A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

Completed
NCT01100333

GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)

Completed
NCT00298025Phase 4

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

Completed
NCT01185704Phase 3

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

Completed
NCT00328926Phase 4

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5